Halozyme Therapeutics Inc (HALO) — Free Cash Flow Generation Index

Latest as of September 2025: 0.98x

Halozyme Therapeutics Inc (HALO) has a Free Cash Flow Generation Index of 0.98x as of September 2025. Free cash flow of $175.57 Million represents 1% of operating cash flow ($178.60 Million). Read Halozyme Therapeutics Inc debt and liabilities for a breakdown of total debt and financial obligations.

FCF Generation Index

0.98x
Free Cash Flow / Operating CF

Free Cash Flow

$175.57 Million
USD

Operating Cash Flow

$178.60 Million
USD

Capital Expenditures

$3.03 Million
USD

Halozyme Therapeutics Inc Free Cash Flow Generation Index (2006–2024)

Historical FCF Generation Index trend for Halozyme Therapeutics Inc across 7 annual periods. Explore HALO capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Annual Free Cash Flow Generation for Halozyme Therapeutics Inc (2006–2024)

Year-by-year Free Cash Flow Generation Index for Halozyme Therapeutics Inc. For the full company profile including market capitalisation, see HALO company net worth.

Year FCG Index Free Cash Flow (USD) Operating CF Capital Expenditures YoY Change
2024 0.98x $468.37 Million $479.06 Million $10.70 Million ▲ +1.8%
2023 0.96x $373.28 Million $388.57 Million $15.29 Million ▼ -2.0%
2022 0.98x $235.30 Million $240.11 Million $4.81 Million ▼ -1.5%
2021 1.00x $297.98 Million $299.44 Million $1.46 Million ▲ +4.2%
2020 0.95x $52.95 Million $55.45 Million $2.50 Million ▼ -3.5%
2017 0.99x $132.70 Million $134.05 Million $1.35 Million ▲ +4.4%
2006 0.95x $6.71 Million $7.08 Million $364.80K
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).